Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib

BACKGROUND: The feasibility of monitoring epidermal growth factor receptor (EGFR) mutations in plasma DNA from patients with advanced non–small cell lung cancer (NSCLC) during treatment with erlotinib and its relation to disease progression was investigated. METHODS: The amount of EGFR-mutant DNA wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorensen, Boe S, Wu, Lin, Wei, Wen, Tsai, Julie, Weber, Britta, Nexo, Ebba, Meldgaard, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303984/
https://www.ncbi.nlm.nih.gov/pubmed/25103305
http://dx.doi.org/10.1002/cncr.28964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303984/
https://www.ncbi.nlm.nih.gov/pubmed/25103305
http://dx.doi.org/10.1002/cncr.28964

Ejemplares similares